User profiles for Richard A Hansen
Richard A. HansenProffessor of Health Outcomes Research and Policy, Auburn University Verified email at auburn.edu Cited by 11018 |
The burden of gastrointestinal and liver diseases, 2006
NJ Shaheen, RA Hansen, DR Morgan… - Official journal of the …, 2006 - journals.lww.com
BACKGROUND Digestive and liver diseases are a source of significant morbidity, mortality,
and health-care costs for the US population. An annual report of the toll of these diseases …
and health-care costs for the US population. An annual report of the toll of these diseases …
Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis
G Gartlehner, RA Hansen, LC Morgan… - Annals of internal …, 2011 - acpjournals.org
Background: Second-generation antidepressants dominate the management of major
depressive disorder (MDD), but evidence on the comparative benefits and harms of these agents …
depressive disorder (MDD), but evidence on the comparative benefits and harms of these agents …
Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis
Background: The comparative effectiveness of rheumatoid arthritis therapies is uncertain.
Purpose: To compare the benefits and harms of disease-modifying antirheumatic drugs (…
Purpose: To compare the benefits and harms of disease-modifying antirheumatic drugs (…
Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis
RA Hansen, G Gartlehner, AP Webb… - … interventions in aging, 2008 - Taylor & Francis
Pharmacologic treatments for Alzheimer’s disease include the cholinesterase inhibitors
donepezil, galantamine, and rivastigmine. We reviewed their evidence by searching MEDLINE ® …
donepezil, galantamine, and rivastigmine. We reviewed their evidence by searching MEDLINE ® …
Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder
Background: Reviews have compared the efficacy and tolerability of newer second-generation
antidepressants with those of placebo or older treatments, but comparative evidence for …
antidepressants with those of placebo or older treatments, but comparative evidence for …
Adherence: comparison of methods to assess medication adherence and classify nonadherence
Background: Medication adherence is suboptimal, and clinicians and researchers struggle
with identifying nonadherent patients. Various measures of medication adherence exist, but …
with identifying nonadherent patients. Various measures of medication adherence exist, but …
[HTML][HTML] Criteria for distinguishing effectiveness from efficacy trials in systematic reviews
Objectives To propose and test a simple instrument based on seven criteria of study design
to distinguish effectiveness (pragmatic) from efficacy (explanatory) trials while conducting …
to distinguish effectiveness (pragmatic) from efficacy (explanatory) trials while conducting …
Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians
Background: Second-generation antidepressants dominate the management of major
depressive disorder, dysthymia, and subsyndromal depression. Evidence on the comparative …
depressive disorder, dysthymia, and subsyndromal depression. Evidence on the comparative …
[HTML][HTML] Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis
…, L Lux, G Gartlehner, RA Hansen… - The Journal of clinical …, 2014 - psychiatrist.com
Objective: To evaluate the efficacy of repetitive transcranial magnetic stimulation (rTMS) in
patients with major depressive disorder (MDD) and 2 or more prior antidepressant treatment …
patients with major depressive disorder (MDD) and 2 or more prior antidepressant treatment …
The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis.
OBJECTIVE: Biologics are an important therapeutic option for treating patients with rheumatoid
arthritis (RA). However, they are associated with rare but severe adverse events such as …
arthritis (RA). However, they are associated with rare but severe adverse events such as …